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Hypoxia has been shown to be an important microenvironmental
parameter influencing tumor progression and treatment efficacy.
Patient guidance for hypoxia-targeted therapy requires evaluation
of tumor oxygenation, preferably in a noninvasive manner. The
aim of this study was to evaluate and validate the uptake of [18F]
HX4, a novel developed hypoxia marker for PET imaging. A het-
erogeneous accumulation of [18F]HX4 was found within rat rhab-
domyosarcoma tumors that was significantly (P < 0.0001) higher
compared with the surrounding tissues, with temporal increasing
tumor-to-blood ratios reaching a plateau of 7.638 ± 0.926 and
optimal imaging properties 4 h after injection. [18F]HX4 retention
in normal tissues was found to be short-lived, homogeneous and
characterized by a fast progressive temporal clearance. Heteroge-
neity in [18F]HX4 tumor uptake was analyzed based on 16 regions
within the tumor according to the different orthogonal planes at
the largest diameter. Validation of heterogeneous [18F]HX4 tumor
uptake was shown by a strong and significant relationship (r =
0.722; P < 0.0001) with the hypoxic fraction as calculated by the
percentage pimonidazole-positive pixels. Furthermore, a causal re-
lationship with tumor oxygenation was established, because com-
bination treatment of nicotinamide and carbogen resulted in
a 40% reduction (P < 0.001) in [18F]HX4 tumor accumulation
whereas treatment with 7% oxygen breathing resulted in a 30%
increased uptake (P < 0.05). [18F]HX4 is therefore a promising can-
didate for noninvasive detection and evaluation of tumor hypoxia
at a macroscopic level.
cancer | nuclear medicine | experimental research
The presence of hypoxic regions due to abnormalities in tumorvasculature, heterogeneously spread within solid tumors
influences clinical outcome; as it is an independent predictor of
poor prognosis-free survival in several types of cancer (1). In
contrast, this unique tumor characteristic makes it an attractive
target for novel drugs to increase the therapeutic effect of con-
ventional cancer treatment modalities. Another approach is the
use of intensity-modulated radiotherapy to give a higher dose to
hypoxic areas while sparing the surrounding normal tissue (2, 3).
Although treatments to counteract the negative effect of intra-
tumoral hypoxia are under investigation, not all patients will ben-
efit from such selective treatments. Therefore, to guide hypoxia-
directed therapies in individual patients, it is important to evaluate
tumor oxygenation using a reliable noninvasive method.
To date, a variety of methods are available for assessment of
tumor oxygenation in solid tumors, of which polarographic oxygen
electrodes and immunohistological assays remain the gold standard
(4). These standard invasive modalities have not yielded reliable
3D images of the whole tumor for clinical use, and therefore re-
search has been focused on noninvasive imaging techniques, such
as positron-emission tomography (PET) using nitroimidazoles.
The 2-nitroimidazole derivative fluoromisonidazole (FMISO) has
been evaluated extensively for different cancer types (5–7).
[18F]FMISO PET imaging has evolved as the gold standard;
however, clinical utility is limited, as there are concerns about
the stability of the fluorine-18 linkage and the formation of
metabolites in blood and urine. Furthermore, only modest signal-
to-noise ratios are obtained due to its slow clearance, high lip-
ophilicity, and liver and gut uptake (8). Second-generation,
more water-soluble 2-nitroimidazoles, such as [18F]-fluoro-
azomycin arabinoside ([18F]FAZA) and [18F]-fluoroerythroni-
troimidazole ([18F]FETNIM), have been validated as hypoxia
markers and have shown lower degradation resulting in higher
tumor-to-background contrast (9, 10). On the other hand, more
lipophilic fluorinated compounds, such as EF3, could be good
alternatives for the detection of tumor hypoxia. However, in
a comparative PET imaging study, we demonstrated no superi-
ority of nitroimidazol-1H-yl-N-[18F]-trifluoropropyl acetamide
([18F]EF3) to [18F]FMISO for the evaluation of hypoxia (11).
Furthermore, it has been shown that the nonnitroimidazole hyp-
oxia marker Copper(II)diacetyl-di(N4-methylthiosemicarbazone)
(Cu-ATSM) is selective for hypoxia in several tumor types. Clin-
ical data obtained from non-small-cell lung cancer (NSCLC)
patients demonstrated the feasibility of 60Cu-ATSM imaging (12).
However, uptake of 64Cu-ATSM in fibrosarcoma-bearing mice
correlated with vascular perfusion as opposed to hypoxia, and the
accumulation did not decrease upon oxygenation using carbogen
breathing (13). Tumor hypoxia response can also be evaluated
by imaging of molecular markers of hypoxia, such as carbonic
anhydrase IX (CAIX) using specific sulfonamides (14).
Alternatively, the 2-nitroimidazole nucleoside analog [18F]HX4
was developed as a potential marker for hypoxic tumor cells. It
represents a novel, click chemistry-based generation of deriva-
tives in which structure–activity relationships, focused on the in-
corporation of a 1,2,3-triazole moiety, have been used to design an
agent with preferred pharmacokinetic and clearance properties
(15). Biodistribution and dosimetry studies in healthy monkeys
and humans showed that the amount of unmetabolized [18F]HX4
in blood and urine samples remained stable, liver and gastroin-
testinal tract uptake was relatively low, and the highest uptake
of [18F]HX4 was found in the urinary bladder, indicating an ex-
cretion primarily through the kidneys (15, 16). Because of the
better water solubility and faster clearance, we hypothesized that
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[18F]HX4 would generate a suitable tumor-to-background signal
ratio earlier compared with other established hypoxiamarkers. The
aim of this study was to evaluate the in vivo uptake of [18F]HX4
over time in an experimental rat tumor model by noninvasive PET
imaging and to define the optimal imaging time point. Secondary
aim was to validate the heterogeneity of the [18F]HX4 accumula-
tion by comparison with the exogenous hypoxia marker pimoni-
dazole, and third aim was to establish a causal relationship between
[18F]HX4 uptake and tumor oxygenation.
Results
Synthesis and Metabolite Analysis. To increase the hydrophilicity
of HX4, a metabolically stable 1,2,3-triazole compound was in-
corporated using the Cu-catalyzed Hüsigen click-chemistry re-
action. Radiolabeling with fluorine-18 afforded [18F]HX4 with
a yield of 3–7 GBq [18F]HX4 at the end of synthesis (14–35%
decay-corrected yield) within 85 min total synthesis time. Ra-
diochemical purity was higher than 95% and specific activity was
typically in the area of 24 GBq/μmol. Calculation of the partition
coefficients confirmed the hydrophilic character of HX4 [logP
(octanol/water) = −0.69 ± 0.02 and logP(octanol/PBS) = −0.68 ±
0.01]. Radio-HPLC analysis showed that >90%, >85%, 60%, and
10% of plasma, urine, kidney, and liver radioactivity, respectively,
represented intact [18F]HX4 60 min after injection.
In Vivo Accumulation of [18F]HX4 in an Experimental Rat Tumor
Model. To evaluate the potential of [18F]HX4 as a noninvasive
marker of hypoxia, a clinically relevant (heterogeneous hypoxic
pimonidazole-positive areas and low-percentage necrosis even at
larger volumes) experimental rat rhabdomyosarcoma R1 tumor
model (5, 11) was used at an average tumor volume of 12.894 ±
5.104 cm3 (Fig. S1A). A clear heterogeneous accumulation of
[18F]HX4 was observed in the tumor (Fig. 1B), whereas equal
[18F]HX4 activity levels were found in surrounding normal tis-
sues. Furthermore, a high accumulation of [18F]HX4 was found
in the bladder, confirming its renal clearance. Quantification of
[18F]HX4 accumulation was done by volume of interest (VOI)
analysis of the heart, hind leg muscles, and tumor. The heart was
selected as reference tissue to noninvasively analyze whole-blood
18F activity, as previously shown (11). Mean [18F]HX4 activity
levels in tumor and muscle tissue were comparable (P = 0.795)
during the first hour after injection (Fig. 1C Left), whereas the
blood pool mean activity level was found to be significantly
higher (P < 0.0001). Maximum activity levels showed a similar
pattern (Fig. 1C Right). No significant differences were observed
between mean and maximum activities in the blood pool (P =
0.566) and muscle (P = 0.227). However, maximum activity
levels in tumors were significantly higher (P = 0.0004) compared
with the corresponding mean accumulation. From 2 h after in-
jection onward, a significantly (P < 0.0001) faster clearance of
[18F]HX4 from the blood and muscle was observed compared
with the tumor (Table S1). This resulted in a significant (P <
0.001) increase in mean tumor-to-blood (T/B) ratios until 4 h
after injection, where a mean T/B of 2.512 ± 0.578 was reached
(Fig. 1D Left). No further increase was observed at later time
points, making 4 h after injection an optimal time point for
[18F]HX4 evaluation in tumors. Because tumors are known to be
heterogeneous, we also analyzed the maximum T/B signal ratios
and found a similar pattern of increase, with a maximum of
7.638 ± 0.926 at 4 h post injection (Fig. 1D Right). A progressive
clearance from normal tissues was observed because muscle-to-
blood (M/B) ratios gradually decreased with time, resulting in
significantly (P < 0.05) lower M/B ratios from 4 h post injection
on. Both mean and maximum [18F]HX4 uptake (percentage
injected radioactivity per mL; %ID/mL) was independent of the
tumor volume (r2 < 0.050; P > 0.4) for all investigated time points.
Pimonidazole Staining, Hypoxic Fraction, and the Relationship with
[18F]HX4 Accumulation. To investigate the relationship between
[18F]HX4 accumulation and pimonidazole hypoxic fraction,
taking into account the heterogeneity in uptake of both chem-
icals, tumors were divided into 16 pieces based on the computed
tomography (CT) image according to their orthogonal planes
(Fig. 2A). HX4 percentage injected dose, based on the PET
image, was heterogeneously distributed across the tumor (Fig. 2
A and B) and ranged from 1 to 19%.
Pimonidazole-positive staining areas (range: 0.713–19.346
mm2) were observed in all tumor pieces, with a heterogeneous
distribution across the pieces (Fig. 2C). Staining was localized in
most cases at a distance (several cell layers) from a perfused
(Hoechst-positive) blood vessel, most often near areas of ne-
crosis, indicative of diffusion-limited hypoxia (Fig. 2D Lower).
However, there is also evidence for the presence of perfusion-
limited hypoxia (Fig. 2D Upper), indicated by pimonidazole-
positive staining in close proximity to perfusion marker-negative
vessels. The hypoxic fraction ranged from 0.006 to 0.146 and was
independent (r = 0.152; P = 0.662) of the tumor volume.
On whole-tumor level, a relationship between [18F]HX4 ac-
cumulation and pimonidazole hypoxic fraction was observed (r=
0.600) but not significant (P = 0.285). On the other hand, on
tumor-regional level, a strong and significant (r = 0.722; P <
0.0001) relationship (Fig. 2E) was observed between the hypoxic
fractions as assessed using [18F]HX4 noninvasive imaging and
pimonidazole staining.
Fig. 1. Heterogeneous [18F]HX4 accumulation occurs at optimal imaging
properties 4 h after injection. (A) Structure of [18F]HX4. (B) Representative CT
and PET/CT image of a rhabdomyosarcoma R1 tumor-bearing rat 4 h after
injection of [18F]HX4. (C) Quantification of mean and maximum [18F]HX4
uptake up to 6 h after injection. Uptake data (n = 21) for tumor (squares),
heart (triangles), and muscles from the hind legs (diamonds) are shown and
data are expressed as mean ± SD %ID/mL. (D) Mean and maximum tissue-to-
blood ratios of [18F]HX4 uptake up to 6 h after injection. Ratios represent
tumor (squares) and muscle (triangles) uptake divided by blood pool uptake.
Data are expressed as mean ± SD. Asterisks indicate significant increase in
tumor-to-blood ratios between individual time points (*P < 0.01, **P <
0.001). NS, not significant.













































[18F]HX4 Accumulation Is Dependent on Available Oxygen. To test
this hypothesis, we used two short-term treatments to modify
tumor oxygenation. To increase or decrease tumor hypoxia,
animals were exposed to an environment containing, respec-
tively, 7% oxygen or a combination of nicotinamide and carb-
ogen. No adverse effects were observed for either treatment
regimen. First, a baseline [18F]HX4 acquisition was performed
on tumor-bearing (13.029 ± 5.149 cm3) animals breathing nor-
mal air. Two days later (volume 15.882 ± 6.284 cm3), animals
were randomized into the two treatment groups and [18F]HX4
accumulation was compared with the baseline uptake. Maximum
[18F]HX4 uptake at the optimal imaging time point in the same
animal was found to be significantly lower (∼40%; P < 0.001)
after treatment with a combination of nicotinamide and carb-
ogen (Fig. 3 A and C). This reduced accumulation persisted over
time until 4 h after injection (Fig. S1B Left) and was lost at later
time points. Also, the mean [18F]HX4 uptake was significantly
lower (P < 0.01) after treatment, but to a smaller extent (25%).
Furthermore, no significant differences in [18F]HX4 accumula-
tion were observed after treating the animals with a combination
of nicotinamide and carbogen for blood and muscle tissue (Table
S2), indicating that normal tissues can indeed cope with changes
in oxygenation. On the other hand, when animals were treated
with 7% oxygen, a significant increase (∼30%; P < 0.05) in
maximum [18F]HX4 uptake in the tumor was observed (Fig. 3 B
and C) persisting over time (Fig. S1B Right). The effect of 7%
oxygen breathing on normal tissues was also negligible (Table
S2). Evaluation of the mean [18F]HX4 activity in the tumor after
7% oxygen treatment resulted in increased accumulation, but
statistical significance was lost. Furthermore, also the mean and
maximum [18F]HX4 uptake after oxygen modification were in-
dependent (r = 0.356; P > 0.3 and r = 0.368; P > 0.3 for 7%
Fig. 2. [18F]HX4 accumulation correlates with the hypoxic fraction of the
tumors. (A) Division of the tumor into 16 pieces based on the CT image
according to their coronal (XY), sagittal (XZ), and transaxial (YZ) planes at
the largest diameter and quartiles. A representative heat map of the dis-
tribution of the percentage HX4 positivity is shown. (B) Representative axial
PET/CT views of the mid and quartile axes of the heat map. (C) Pseudocol-
ored gray-value images of the areas highlighted in the axial PET/CT views
showing pimonidazole staining (green), vessels (red), and perfusion (blue).
(D) Higher-magnification images of the areas highlighted in the original
stainings. Areas of perfusion-limited (white) or diffusion-limited (gray)
hypoxia are indicated with arrowheads. (E) Relationship at the regional level
(n = 76) between [18F]HX4 accumulation and pimonidazole hypoxic fraction.
Fig. 3. [18F]HX4 accumulation depends on tumor oxygenation. (A and B)
Representative set of CT and PET/CT images within the same animal 4 h after
injection of [18F]HX4 before and after treatment (interval of 2 d) with (A)
a combination of nicotinamide and carbogen or (B) 7% oxygen breathing.
Images are scaled to the maximum-intensity values of all images. (C)
Quantification of maximum [18F]HX4 uptake in animals treated (white bars)
with nicotinamide and carbogen (n = 7) or 7% oxygen breathing (n = 6)
compared with no treatment (black bars) at the optimal imaging time point
4 h after injection. Data are expressed as mean ± SD. Asterisks indicate
significant difference (*P < 0.05, **P < 0.001) compared with no treatment.



































oxygen breathing or a combination of nicotinamide and carb-
ogen, respectively) of the tumor volume.
Discussion
Increasing evidence points to an important role for tumor hyp-
oxia in sensitivity to radio- and chemotherapy (9), indicating the
necessity to evaluate oxygenation in individual tumors. Over the
last decade, noninvasive methods that can identify tumors with
substantial hypoxic fractions have been developed and may be
used to acquire knowledge of the variations in spatial distribu-
tion of hypoxia (4). PET using the 2-nitroimidazole [18F]FMISO
holds promise for the evaluation of tumor hypoxia at both global
and local levels. Several alternative nitroimidazole derivatives
have been developed to overcome some of the limitations of
[18F]FMISO such as nonspecific retention, metabolic conversion,
and low partition coefficient, all leading to faster clearance
properties (8).
In the current study, we evaluated the in vivo oxygen-de-
pendent uptake of [18F]HX4, a novel 2-nitroimidazole nucleo-
side analog PET tracer, in a rat tumor model. The Cu-catalyzed
Hüsigen click-chemistry reaction was used to incorporate a met-
abolically stable 1,2,3-triazole moiety, resulting in increased hy-
drophilicity of HX4 evidenced by the lower logP value (−0.69 ±
0.02) compared with FMISO (−0.40 ± 0.02), FAZA (0.04), and
EF3 (0.05) (17–20). Unexpectedly, incorporation of the 1,2,3-
triazole moiety improved the clearance properties relative to
FMISO, demonstrating that kidney-bladder is the major HX4
excretion pathway (15) whereas FMISO clearance mainly occurs
through the hepatobiliary and gastrointestinal pathway (Table
S3). Additionally, when clearance shifts more toward the renal
pathway, less metabolism is expected. Metabolite analysis showed
>90%, >85%, 60%, and 10% intact [18F]HX4 in plasma, urine,
kidney, and liver, respectively. It should be noted that the per-
centage injected dose corrected for weight (%ID/g) of [18F]HX4
in liver is <0.3% (15), indicating that the majority of [18F]HX4
remained intact. For [18F]FMISO the highest activity was found in
liver and intestines (Table S3), and intact [18F]FMISO in plasma,
urine, kidney, and liver were 47%, 77%, 3%, and 3%, respectively
(18). Our data strongly suggest that the hydrophilic [18F]HX4,
cleared through the kidneys, will result in a faster decrease of the
background signal, leading to a larger imaging window and an
increased biostability profile.
We observed a clear [18F]HX4 accumulation in tumors com-
pared with the surrounding normal tissue and a progressive de-
crease in concentration with time. A mean T/B ratio of 2.515 ±
0.578 was observed 4 h after injection, higher than the described
cutoff value (T/B > 1.4) indicative for significant hypoxia
obtained from [18F]FMISO imaging of several human tumors
(21). No further increase was observed at later time points,
making 4 h after injection an optimal time point for [18F]HX4
evaluation in tumors. A large heterogeneity in uptake, imaging
time, and tumor and animal models for different hypoxia markers
have been observed in the literature, making comparison hard to
interpret. Table S4 provides a summary of animal studies with 2-
nitroimidazole-based hypoxia markers [18F]FMISO, [18F]FAZA,
[18F]EF3, nitro-1H-imidazol-1-yl-N-[18F]-pentafluoropropyl acet-
amide ([18F]EF5) and [18F]FETNIM (structures in Fig. S1C).
Most studies have focused on [18F]FMISO, and a broader range
in T/B or T/M (tumor-to-muscle) ratios was observed for ro-
dent (2.04–11) compared with human (1.28–5.7) tumor models.
Also, imaging occurred relatively fast (2–3 h) after injection. For
[18F]FAZA, a similar broader range for rodent (2.9–9.82) as for
human (2.0–6.1) tumor models was found, but at a later time
(3 h). For the other hypoxia markers, no data are available on
human tumor models, but a trend has been noticed for imaging at
even later time points (3–5 h). Although characterization of new
hypoxia markers should be preferably performed in multiple
cancer models, highly additive data can be expected from com-
parisons of different tracers in the same tumor models. We found
that [18F]HX4 uptake in this rhabdomyosarcoma model was
generally lower both in normal and in tumor tissue compared
with previously reported [18F]EF3 activities (11), resulting in
comparable mean T/B ratios. As tumors are known to be het-
erogeneous, we also analyzed the maximum T/B uptake at 4 h
post injection and observed an almost twofold increased T/B
(7.638 ± 0.926) for [18F]HX4 compared with [18F]EF3 (4.84 ±
0.23) (11). This suggests that [18F]HX4 in this model reflects
better on tumor heterogeneity and the extent of hypoxia.
Heterogeneous patterns of [18F]HX4 accumulation were seen
across different tumor regions, as exemplified by high-count
density regions in a rim of the tumor surrounding a central part
of low radioactivity reflecting diffusion-limited hypoxia and
regions with a hot spot distribution representing perfusion-
limited hypoxia. Similar heterogeneous uptake patterns were
previously observed for [18F]FMISO and [18F]EF3 in the same
model (5, 11). Also, in other species bearing tumors, heteroge-
neous patterns of hypoxia marker accumulation have been ob-
served. Imaging of [18F]FMISO uptake in xenograft-bearing
mice demonstrated both high focal and more patchy distribution
of the hypoxia PET tracer (22). These heterogeneous patterns of
accumulation can be explained by the way vascular structures,
responsible for the tracer influx and washout, are organized
within the tumor. Regions with strong [18F]HX4 accumulation
surrounding necrotic or normoxic areas receive their blood
supply from vascular sheets, whereas regions demonstrating
a more diffuse uptake are supplied from a central vessel (23).
Microregional distribution of hypoxia was assessed using im-
munohistochemical staining of the bioreductive hypoxia marker
pimonidazole, a compound known to give a reliable estimate of
radiobiologically relevant hypoxia (24). A comparable pattern
in heterogeneous staining was observed for pimonidazole, with
evidence for the presence of both diffusion- and perfusion-
limited hypoxia at a distance or in close proximity to vessels,
respectively. Within tumor areas, a strong and significant
correlation was observed between the percentage positivity for
[18F]HX4 and pimonidazole. The hypoxic fractions were used,
because they have been shown to be a more robust parameter for
tumor hypoxia than that based on intensity profiles (22). When
heterogeneity was not taken into account, whole-tumor mean or
maximum [18F]HX4 accumulation was not significantly corre-
lated with a pimonidazole-obtained hypoxic fraction. It has been
shown that independent of the statistical methodology at least
three, but preferably four or five tumor core biopsies from dif-
ferent tumor regions, are required to cover tumor heterogeneity
(25). Ideally, to analyze microregional tumor heterogeneity,
voxel-to-voxel analysis should be performed, but this is practi-
cally only feasible when autoradiography sections are avail-
able. Using this method, significant correlations between
pimonidazole-obtained hypoxic fraction and [18F]FMISO (22)
and [18F]FAZA (26) accumulation were observed.
Furthermore, a causal relationship was found between
[18F]HX4 accumulation and tumor oxygenation, because a sig-
nificant reduction in uptake was observed within the same animal
when [18F]HX4 was injected after a treatment combining nico-
tinamide and carbogen. This combination treatment has been
shown to reduce tumor hypoxia in both preclinical and clinical
practice (27, 28). Carbogen breathing is known to reduce chronic
hypoxia by increasing the oxygen diffusion distance, whereas
nicotinamide prevents intermittent vascular shutdown, resulting
in a reduction in perfusion-limited hypoxia (29, 30). Furthermore,
[18F]HX4 accumulated in tumors after 7% oxygen breathing,
lending further support that HX4 acts as a sensitive and reversible
tumor hypoxia marker in vivo. A similar increase in mean
[18F]FMISO intensity was observed in a glioblastoma model after
clamping (22). The effect of the oxygen modification treatment
persisted ∼4 h, in agreement with the observed decrease in
[18F]EF3 accumulation in FSA II tumor-bearing mice breathing
carbogen (18). Although studies have investigated the oxygen
dependence of several noninvasive hypoxia markers using auto-
radiography or biodistribution studies, only a few demonstrated
this dependency using PET imaging. For example, [18F]FMISO
ratios of tumor to reference tissues significantly decreased upon













































carbogen/oxygen breathing in different murine tumor models
(27). Also, for serial animal [18F]FAZA PET marker studies,
a significant reduction in tumor-to-background ratios was
obtained after breathing pure oxygen or carbogen (31, 32).
[18F]HX4 biodistribution in normal tissues was found to be fast
and homogeneous, as has already been published for [18F]EF3
and [18F]FMISO in the same rat model (11). The low uptake
levels of [18F]HX4 in intestines, liver, kidney, and other normal
tissues result in lower background signals, providing good imaging
properties. A progressive clearance was observed with time and
the uptake in muscle was always lower than in the blood.
[18F]HX4M/B ratios were comparable to [18F]EF3M/B ratios 2 h
after injection, but whereas [18F]EF3 ratios remained equal with
time (11), [18F]HX4 ratios decreased, indicating a faster clear-
ance from normal tissues. This is in agreement with dosimetry
data obtained in healthy humans 4 h after injection, where the
absorbed doses for most organs were lower for [18F]HX4 com-
pared with [18F]FMISO and [18F]FETNIM, except for the kid-
neys and bladder (16). This is, however, not surprising, because
the highest [18F]HX4 uptake was found in the urinary bladder,
confirming excretion primarily through the kidneys. To reduce
bladder and kidney dose, patients should therefore be encour-
aged to maintain adequate hydration and void frequently (15, 16).
Our results demonstrate that noninvasive nuclear imaging of
tumor oxygenation at a macroscopic level using [18F]HX4 is
possible and agrees with the overall hypoxic fraction. This indi-
cates that [18F]HX4 PET would be a valuable tool for therapy
prediction and response evaluation. Pre-therapy [18F]FMISO
uptake has been shown to be an independent predictor for out-
come in head and neck cancer patients (7), and [18F]FMISO
uptake patterns after therapy correlated well with the tumor re-
sponse (6). Additionally, the well-established clearance properties
of [18F]FMISO appear to be minimally different between rodents
and humans (33), and given that both [18F]FMISO and [18F]HX4
localize to hypoxic tissues as a result of the 2-nitroimidazole, the
ability of [18F]HX4 to perform similarly in humans is not an un-
reasonable prediction. This also suggests that the faster [18F]HX4
clearance rates found in rodents would similarly apply to humans.
The clinical applicability of [18F]HX4 was demonstrated in a
phase 1 study in NSCLC patients with no obvious toxicity (34).
Furthermore, a heterogeneous [18F]HX4 accumulation was ob-
served (Fig. 4) with a substantial increase in T/M ratios in the
second hour after injection. Because imaging was performed in
end-stage patients and no optimal imaging time point could be
defined, future clinical trials using [18F]HX4 should investigate
and explore (i) imaging at later time points, (ii) the capacity to
evaluate and predict therapy response, and (iii) the possibility of
applying dose painting or similar dose escalation strategies to
hypoxic regions.
Conclusion
[18F]HX4 has been shown to be a promising in vivo tracer for the
noninvasive detection and evaluation of tumor hypoxia. Both
in preclinical models as well as in patients, a heterogeneous
[18F]HX4 accumulation was observed with optimal imaging
properties 4 h after injection and a strong dependency on tumor
oxygenation. A strong significant correlation was found between
[18F]HX4 accumulation and the hypoxic fraction of the tumors
as measured by pimonidazole staining. [18F]HX4 retention in
normal tissues was found to be short-lived, homogeneous and
characterized by a progressive temporal clearance. Taken to-
gether, our results indicate that [18F]HX4 is a good candidate for
hypoxia assessment in vivo at a macroscopic level and may find
clinical utility in image-guided and intensity-modulated radio-
therapy applications.
Materials and Methods
Animal and Tumor Model. All procedures and experiments were approved by
the Animal Ethical Committee of the University ofMaastricht (KdVR/ND 2008-
135). Adult male WAG/Rij rats (275 ± 19 g) were implanted s.c. with syn-
geneic rhabdomyosarcomas (1-mm3 R1 tumors) in the lateral flank. Experi-
ments were started on average 42 d after transplantation, when tumors
reached an average volume of 12.894 ± 5.104 cm3 (Fig. S1A).
Synthesis and Metabolite Analysis. 3-[18F]fluoro-2-(4-((2-nitro-1H-imidazol-
1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol ([18F]HX4; Fig. 1A) was syn-
thesized from the precursor: 3-(formyloxy)-2-{4-[(2-nitro-1H-imidazol-1-yl)
methyl]-1H-1,2,3-triazol-1-yl}propyl 2-nitrobenzenesulfonate (16) supplied
by Siemens Molecular Imaging. [18F]HX4 was obtained by nucleophilic sub-
stitution of 2-nitrobenzenesulfonate ester with [18F]fluoride in acetonitrile/
t-butanol with Kryptofix-2.2.2 and K2CO3 followed by acidic hydrolysis. The
product was isolated from the crude reaction mixture by HPLC and refor-
mulated into a sterile, isotonic, and pyrogen-free saline solution containing
7.09 mM sodium hydrogen phosphate and 10 mg/mL ascorbic acid. The
product was stable in the formulation solution for at least 6 h at room
temperature. Solutions of HX4 at 0.2–50 μg/mL were prepared in a mixture
(1:9) of n-octanol and water or phosphate buffer (pH 7.4) to measure logP
values. Samples (100 μL) from both phases were analyzed by HPLC (Phe-
nomenex Gemini C18 column, 4.5 × 150 mm, flow 1 mL/min, UV 330 nm) for
quantitative measurements. The percentages of intact HX4 in plasma, urine,
kidney, and liver 60 min after injection were analyzed by HPLC.
Experimental Design. Before and during PET acquisition, rats were anes-
thetized with sodium pentobarbital (60 mg/kg, i.p.). The radiolabeled tracer
was administered into a lateral tail vein via an i.v. line (Venoflux 0.4 mm G27)
flushed with diluted heparin saline solution. Pretreatment with nicotinamide
(500 mg/kg, i.p.), carbogen (95% O2, 5% CO2), and 7% oxygen (residual N2)
breathing occurred as previously described (14).
Rat Imaging Acquisition. Imaging was performed using a dedicated PET/CT
Biograph scanner (SOMATOM TruePoint Sensation-40 with an ECAT ACCEL
PET scanner; Siemens) with an axial field of view (FoV) of 162mm, a transaxial
FoV of 605 mm, and a spatial resolution of 5.3 mm FWHM at the center of the
FoV. The acquired CT images were used for attenuation correction of the PET
data. Also, corrections for scatter (3D), randoms, dead time, and decay of the
injected radionuclides were applied. After acquiring a topogram, a whole-
body CT scan was acquired using a 1-mm reconstructed slice thickness and
a pitch of 0.8. Simultaneously with tracer injection (20.430 ± 2.418 MBq),
a dynamic emission scan in list mode (LM) was started for 60 min in one bed
position encompassing the heart, tumor, and hind legs of the rat. Afterward,
LM data were rebinned using Fourier rebinning, and PET images were
reconstructed as previously described (5). Two hours post injection, the rats
were repositioned using external markers and a dedicated laser-positioning
system (LAP) for a CT scan, immediately followed by a second dynamic
emission scan performed for 20 min (rebinned into four frames of 5 min
each). The same sequence was repeated each hour until 6 h after injection.
PET Image Analysis. The reconstructed PET/CT images were viewed and an-
alyzed in dedicated software (TrueD VC60; Siemens). PET and CT images were
automatically and rigidly registered based on a mutual information algo-
rithm. Activity data (Bq/mL) in tumor, muscle, and blood pool (heart) were
obtained by manual delineation of a VOI in the fused PET/CT images. All
activity data were corrected for fluorine-18 decay toward injection time and,
to minimize partial volume effects, recovery coefficients were calculated and
applied to all of the data. Quantification of the data was done by calculation
of the %ID/mL and T/B activity ratios. From the fused PET/CT images (for raw
data see http://www.cancerdata.org), the tumors were divided based on the
tumor contour manually drawn on the last time point CT image in 16 regions
according to their coronal (XY), sagittal (XZ), and transaxial (YZ) planes at
the largest diameter (Fig. 2A). The transaxial plane was further divided
according to the quartiles. For each region, the total number of [18F]HX4-
Fig. 4. Representative transaxial (Left) and coronal (Right) [18F]HX4 PET/CT
image of an NSCLC patient. [18F]HX4 accumulation is shown within the gross
tumor volume (GTV) delineated based on the CT image.



































positive voxels (above background) was assessed and divided by the number
of voxels in the tumor VOI to calculate the percentage [18F]HX4 positivity.
Immunohistochemical Staining and Analysis. The exogenous hypoxia marker
pimonidazole hydrochloride (PIMO; 60 mg/kg, i.p.) and the perfusion marker
Hoechst 33342 (15 mg/kg, i.v.) were injected 1 h and immediately before
euthanizing the animals, respectively. From each region, 5-μm sections were
cut and mounted on poly-L-lysine-coated slides. After fixation in cold ace-
tone, slides were scanned for fluorescent signal of Hoechst before staining
for PIMO and vessels. Staining was done as previously described (22), using
rabbit anti-pimonidazole (1:1,000; gift of J. A. Raleigh., University of North
Carolina, NC) and goat anti-collagen IV (1:100; Southern Biotechnology As-
sociation). Grayscale images for each staining were obtained and converted
into binary images. After thresholding above background staining for each
individual marker, the hypoxic fraction represented as the ratio of the sum
of all PIMO-positive pixels and the sum of all tumor pixels, including areas of
necrosis, was calculated.
Statistics.All statistical analyses were performedwith GraphPad Prism version
5.01 for Windows. An unpaired Student’s t test and nonparametric Mann–
Whitney U test for small groups were used to determine the statistical sig-
nificance of differences between two independent groups of variables.
Linear regression analysis was used to assess correlations (Spearman’s r)
between the different parameters. For all tests, P < 0.05 was considered
significant.
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